{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-004707","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2026-06-10T20:15:25+00:00","discovered_at":"2026-06-10T20:17:00.345159+00:00","generated_at":"2026-06-10T20:23:48.288121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort","bullets":["Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.","Cash $5.0M at March 31; subsequent $1.85M raised via ATM program.","Australian oncology study advanced to Cohort 3; first patient treated in final dosing cohort.","Patents issued in US and Europe for Hemopurifier in long COVID/coronavirus, extending protection to 2040s.","Preclinical studies for rheumatoid arthritis and chronic kidney disease underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004707","json":"https://secwatch.observer/filing/0001683168-26-004707.json","markdown":"https://secwatch.observer/filing/0001683168-26-004707.md","text":"https://secwatch.observer/filing/0001683168-26-004707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/0001683168-26-004707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:23:48.288121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b6168e8bac5d06065d38a799dfc26e8beeccff3","claim":"AETHLON MEDICAL INC reported financial results for the fiscal year ended March 31, 2026.","evidence_excerpt":"Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/0001683168-26-004707-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}